Thymopentin (TP-5) therapy during lymphadenopathy syndrome (LAS/ARC): preliminary report. NLM AIDSLINE Important note: Information in this article was accurate in 1988. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Thymopentin (TP-5) therapy during lymphadenopathy syndrome (LAS/ARC): preliminary report.

J Exp Pathol. 1987 Summer;3(4):705-12. Unique Identifier : AIDSLINE MED/88316475
Costigliola P; Ricchi E; Colangeli V; Pintori C; Boni P; Chiodo F; Istituto di Malattie Infettive, Bologna.

Abstract: Persistent generalized lymphadenopathy during HIV infection is now a well classified syndrome featuring multiple chronic lymph node enlargement frequently associated with further symptoms (diarrhea, nocturnal sweating, loss of weight, fever): it is invariably accompanied by serious alterations of the cell-mediated immunity including lymphopenia, reduced number of helper lymphocytes in circulation, inversion of the helper/suppressor ratio, lower proliferative response in vitro and deficient delayed skin sensitivity tests. Minor opportunistic infections are also more frequent, the most widespread being chronic oral candidiasis. Whenever several of these signs are associated in a single patient, especially if the immunitary deficit is severe, an immunomodulating treatment is indicated to improve the lymphocyte functionality and finally to modify any evolutive tendency. The Authors give the preliminary results of a pilot study carried out on 12 patients with LAS/ARC treated with Thymopentin at a dosage of 50 mg by intra muscular injection on alternate days for cycles of 30 days. Compared with 14 untreated patients, the subjects receiving therapy showed a more stable immunological picture, and improvement in subjective symptoms and a better therapeutic response to minor opportunistic infections.
Keywords: Adjuvants, Immunologic/*THERAPEUTIC USE AIDS-Related Complex/*THERAPY Human Leukocyte Count Lymphocytes/IMMUNOLOGY Peptide Fragments/*THERAPEUTIC USE Thymopoietins/*THERAPEUTIC USE Thymus Hormones/*THERAPEUTIC USE JOURNAL ARTICLE

KWDadjuvants,immunologic/KWDtherapeuticuseaids-relatedcomplex/KWDtherapyhumanleukocytecountlymphocytes/immunologypeptidefragments/KWDtherapeuticusethymopoietins/KWDtherapeuticusethymushormones/KWDtherapeuticusejournalarticle
881230
M88C0605

Copyright © 1988 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1988. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1988. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .